The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has confirmed its previous negative opinion on the application for new indication for Cymbalta (duloxetine) for the treatment of moderate to severe chronic somatic pain in patients not taking NSAIDs regularly. After considering the grounds for re-examination of the opinion as requested by the company, and a re-examination of the initial opinion, the CHMP confirmed the refusal of the change to the marketing authorisation.